Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Annals of Internal Medicine

• Publication date

  1993-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-118-10-199305150-00002PMID 8097082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.

  1992cited by this paper
• Correlation between CD4 cell counts and cellular and plasma viral load in HIV-1-seropositive individuals.

  1991cited by this paper
• Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease.

  1990cited by this paper
• Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

  1990cited by this paper
• A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

  1990cited by this paper
• 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.

  1990cited by this paper
• The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

  1990cited by this paper
• Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.

  1990cited by this paper
• Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.

  1990cited by this paper
• The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial

  1990influential reference
• A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome

  1990influential reference
• Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

  1990influential reference
• Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.

  1989cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper
• Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.

  1989cited by this paper
• Plasma viremia in human immunodeficiency virus infection.

  1989cited by this paper
• Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex

  1989influential reference
• Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

  1989cited by this paper
• Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

  1989cited by this paper
• Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS.

  1988influential reference
• Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

  1988influential reference
• The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

  1987influential reference
• The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

  1987influential reference
• Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

  1986cited by this paper
• Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir.

  1982cited by this paper

• Improving and validating data-driven genotypic interpretation systems for the selection of antiretroviral therapies

  2016cites this paper
• The Discovery and Development of Antiretroviral Agents

  2014cites this paper
• Infectious and Granulomatous Peripheral Neuropathies

  2014cites this paper
• Biowaiver monographs for immediate-release solid oral dosage forms: Zidovudine (azidothymidine).

  2013influential citation
• Zidovudine

  2012cites this paper
• The Effects of Long Term Zidovudine Therapy and Pneumocystis carinii Prophylaxis on HIV Disease

  2012cites this paper
• The history of antiretroviral therapy and of its implementation in resource-limited areas of the world

  2012cites this paper
• Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection

  2011cites this paper
• Distal Sensory Polyneuropathy and Other Selected Neuropathies in HIV Infection

  2009cites this paper
• Nonclinical Safety Profile of Telbivudine, a Novel Potent Antiviral Agent for Treatment of Hepatitis B

  2008cites this paper
• Factors associated with different responses to combination antiretroviral therapy in an observational cohort study of HIV-1 infected patients

  2008cites this paper
• Understanding and avoiding antiretroviral adverse events.

  2006cites this paper
• Peripheral Neuropathy Associated With Nucleoside Reverse Transcriptase Inhibitor Therapy

  2006cites this paper
• New concepts in anti-HIV therapies

  2006cites this paper
• Chapter 114 – Neuropathy Caused by Drugs

  2005cites this paper
• Nucleoside Analogues Toxicities Related to Mitochondrial Dysfunction: Focus on HIV-Infected Children

  2005cites this paper
• Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystic carinii Pneumonia (PCP) before AIDS diagnosis in Italy

  2004cites this paper
• HIV neuromuscular disease and mitochondrial function.

  2004cites this paper
• Chapter 18 – Neurologic Complications of HIV and AIDS

  2003cites this paper
• Toxicological study of the anti-HBV agent β-L-thymidine

  2003cites this paper
• Sektion II Praxis

  2003cites this paper
• Current treatment of HIV infection.

  2003cites this paper
• Antiretroviral therapy and resistance to antiretroviral drugs.

  2002cites this paper
• Chapter 1 Randomized Controlled Trials: Methodology, Outcomes, and Interpretation

  2001cites this paper
• Peripheral neuropathy and antiretroviral drugs

  2001influential citation
• Mitochondrial Alterations with Mitochondrial DNA Depletion in the Nerves of AIDS Patients with Peripheral Neuropathy Induced by 2′3′-Dideoxycytidine (ddC)

  2001influential citation
• Regulatory issues in the era of highly active antiretroviral therapy.

  2000cites this paper
• Management of the adverse effects of antiretroviral therapy and medication adherence.

  2000cites this paper
• Anti-Retroviral Therapy and Resistance to Anti-Retroviral Drugs

  2000cites this paper
• Peripheral neuropathy: zalcitabine reassessed

  2000cites this paper
• HIV therapeutics: past, present, and future.

  2000cites this paper
• Acute pancreatitis in human immunodeficiency virus-infected patients: a review.

  1999cites this paper
• Quality of Life Outcomes of Saquinavir, Zalcitabine and Combination Saquinavir plus Zalcitabine Therapy for Adults with Advanced HIV Infection with CD4 Counts between 50 and 300 Cells/mm3

  1999cites this paper
• Changing treatment patterns among patients with HIV: Royal Free Hospital 1987–97

  1999cites this paper
• Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.

  1999cites this paper
• Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised e vidence

  1999cites this paper
• CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group

  1998cites this paper
• Zalcitabine Population Pharmacokinetics: Application of Radioimmunoassay

  1998cites this paper
• The Effects of Renal Impairment on the Pharmacokinetics of Zalcitabine

  1998cites this paper
• Les traitements antirétroviraux

  1997cites this paper
• Management of Asymptomatic HIV Infection

  1997cites this paper
• The pancreas in AIDS.

  1997cites this paper
• Meta-analysis for the evaluation of potential surrogate markers.

  1997cites this paper
• Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group.

  1997cites this paper
• A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS‐related complex

  1997cites this paper
• The relationship between study design, results, and reporting of randomized clinical trials of HIV infection.

  1997cites this paper
• [Endocrine disorders and hormonal therapy in HIV infections].

  1997cites this paper
• Antiretroviral agents. Current usage.

  1997cites this paper
• [Antiretroviral treatment in human immunodeficiency virus infection].

  1997cites this paper
• Recent advances in antiretroviral therapy and HIV infection monitoring.

  1997cites this paper
• Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group.

  1996cites this paper
• Survival in HIV-Infected Patients Who Have Received Zidovudine: Comparison of Combination Therapy with Sequential Monotherapy and Continued Zidovudine Monotherapy

  1996cites this paper
• Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.

  1996cites this paper
• Antiretroviral therapy in adults.

  1996cites this paper
• Zidovudine: anno 1995.

  1996cites this paper
• Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome‐related lymphoma: Effect on human immunodeficiency virus and serum interleukin‐6 levels over time

  1996cites this paper
• Combination antiretroviral therapy in HIV infection. An economic perspective.

  1996cites this paper
• Endocrine Implications of Human Immunodeficiency Virus Infection

  1996cites this paper
• ddC (zalcitabine).

  1996cites this paper
• Health-related quality of life of HIV-infected women: evidence for the reliability, validity and responsiveness of the Medical Outcomes Study Short-Form 20

  1996cites this paper
• State of the art. Antiviral treatment of HIV infection.

  1996cites this paper
• Antiviral Chemotherapy 4

  1996cites this paper
• Primary care of the HIV patient: standard practice and new developments in the era of managed care.

  1996cites this paper
• Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

  1996cites this paper
• The role of antiretroviral therapy in the management of HIV infection in women.

  1996cites this paper
• Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.

  1996cites this paper
• Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme.

  1996cites this paper
• Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.

  1996cites this paper
• Combination Antiretroviral Therapy in HIV Infection

  1996cites this paper
• Les anti-rétroviraux

  1996cites this paper
• Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel

  1996cites this paper
• What is the Question

  1996cites this paper
• STATE OF THE ART

  1996cites this paper
• Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents

  1995cites this paper
• The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature.

  1995cites this paper
• Efficacy and Toxicity of Long-Term Administration of 2′,3′-dideoxycytidine in the LP-BM5 Murine-Induced Immunodeficiency Model

  1995cites this paper
• Erythema Multiforme Secondary to Dideoxycytidine (ddC)

  1995cites this paper
• Controversies in anti-retroviral therapy of adults.

  1995cites this paper
• Viral phenotype and genotype as markers in clinical trials.

  1995cites this paper
• Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection.

  1995cites this paper
• Validity of the Karnofsky Performance Status in an HIV-infected sample.

  1995cites this paper
• Zalcitabine‐associated pharyngeal ulcers

  1995cites this paper
• Statistical issues in the design of HIV vaccine trials.

  1995cites this paper
• Antiretroviral Strategies Revisited

  1995cites this paper
• A Comparison of Zidovudine, Didanosine, Zalcitabine and No Antiretroviral Therapy in Patients with Advanced HIV Disease

  1995cites this paper
• Antiretroviral therapy: reference guide to major clinical trials in patients infected with human immunodeficiency virus.

  1995cites this paper
• Acute necrotico-hemorrhagic pancreatitis after famciclovir prescription.

  1995cites this paper
• Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.

  1995cites this paper
• [Treatment of HIV infection with nucleoside analogs: present status].

  1995cites this paper
• Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1.

  1995cites this paper
• Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease

  1995cites this paper
• Surrogate markers in AIDS and cancer trials.

  1994cites this paper
• 10 Pancreatic lesions in HIV-infected patients

  1994cites this paper
• Surrogate markers in aids and cancer trials

  1994cites this paper
• [Antiretroviral therapy. Current status and perspectives].

  1994cites this paper
• In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection.

  1994cites this paper
• Perspectives on the use of antiretroviral drugs in the treatment of HIV infection.

  1994cites this paper
• Inhibitors of HIV proteinase

  1994cites this paper
• Pancreatic lesions in HIV-infected patients.

  1994cites this paper
• Management of antiretroviral drug therapy in human immunodeficiency virus infection.

  1994cites this paper